Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Surgery 1Stress, Psychological 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Seminoma 1Sarcoma 1Recurrence 1Postoperative Complications 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1Multiple Myeloma 1Medulloblastoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Intermittent Fasting 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 14Paclitaxel 12pembrolizumab 9Fluorouracil 7Radiotherapy 6Irinotecan 5Esophagectomy 5tislelizumab 4Oxaliplatin 4Leucovorin 4Drug Therapy 4Carboplatin 4toripalimab 3Levoleucovorin 3Docetaxel 3Capecitabine 3camrelizumab 2Taxes 2Radiation 2Nivolumab 2Injections 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1palbociclib 1nimotuzumab 1nazartinib 1lenvatinib 1ivarmacitinib 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Neoadjuvant Therapy × 90 days × Clear all
NCT07244978 2026-04-24

Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
49 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡